Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Recommendation of “Hold” by Analysts

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $77.1667.

Several brokerages recently weighed in on CORT. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research note on Wednesday, December 31st. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a report on Friday, January 23rd. HC Wainwright reduced their price target on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Finally, UBS Group assumed coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price on the stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright keeps a constructive stance — the firm retained a “Buy” rating and a $67 price target and revised some near-term quarterly EPS forecasts upward (Q1–Q3 adjustments), providing continued analyst support for the story. HC Wainwright Research Note
• Neutral Sentiment: Short-interest report shows no meaningful reported short position (entry shows 0 shares / 0.0 days), so today’s move is unlikely driven by short-covering or a jump in new short activity. (Data in the filing appears anomalous.)
• Neutral Sentiment: Market commentary and analysis pieces question whether current pricing fully reflects the stock’s steep one‑year decline and ongoing operational risks — useful background but not an immediate catalyst. Is Corcept Pricing Reflect Its Decline (Yahoo)
• Neutral Sentiment: Post‑earnings coverage and summaries highlight a mixed picture from the Q4 call (growth but rising risks); these recaps inform investor expectations but are not new filings. TipRanks Earnings Recap
• Negative Sentiment: Multiple securities class‑action suits and dozens of plaintiff‑solicitation notices were announced this week, alleging securities law violations for the period Oct 31, 2024–Dec 30/31, 2025. Several national firms are seeking lead plaintiffs (April 21, 2026 deadline), creating legal overhang, potential defense costs and settlement risk. Rosen Law Firm Notice Hagens Berman Alert
• Negative Sentiment: HC Wainwright lowered medium‑ and long‑term earnings forecasts (FY2026–FY2030 cuts across multiple years), signaling reduced analyst expectations for structural revenue/profitability growth; downward revisions can pressure valuation and investor confidence despite the maintained Buy rating. HC Wainwright Estimates Update

Insider Buying and Selling

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the sale, the insider directly owned 1,235 shares in the company, valued at $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 60,000 shares of company stock worth $3,122,600. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors have recently modified their holdings of the business. Torren Management LLC purchased a new position in Corcept Therapeutics in the fourth quarter valued at approximately $25,000. Advisory Services Network LLC acquired a new position in Corcept Therapeutics in the 3rd quarter valued at about $25,000. Clearstead Advisors LLC raised its stake in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in Corcept Therapeutics during the 2nd quarter worth $28,000. Finally, Atlas Capital Advisors Inc. acquired a new stake in Corcept Therapeutics in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

Shares of CORT opened at $35.70 on Monday. The company has a market capitalization of $3.80 billion, a P/E ratio of 43.54 and a beta of 0.29. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $117.33. The business’s 50-day moving average is $44.41 and its two-hundred day moving average is $65.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 earnings per share. Research analysts predict that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.